Skip Navigation LinksHome > January 2014 - Volume 24 - Issue 1 > Synchronous Ovarian and Endometrial Cancer—an International...
International Journal of Gynecological Cancer:
doi: 10.1097/IGC.0000000000000019
Ovarian Cancer

Synchronous Ovarian and Endometrial Cancer—an International Multicenter Case-Control Study

Heitz, Florian MD*†; Amant, Frederic MD, PhD; Fotopoulou, Christina MD, PhD§; Battista, Marco J. MD; Wimberger, Pauline MD, PhD¶#; Traut, Alexander*†; Fisseler-Eckhoff, Annette MD, PhD**; Harter, Philipp MD*†; Vandenput, Ingrid MD; Sehouli, Jalid MD, PhD§; Schmidt, Marcus MD, PhD; Kimmig, Rainer MD, PhD; du Bois, Rabea*†; du Bois, Andreas MD, PhD*†

Collapse Box

Abstract

Objectives

This study aimed to compare the prognosis of patients with synchronous endometrial and ovarian cancer (SEOC) to matched controls with either endometrial cancer (EC) or ovarian cancer (OC).

Methods

A retrospective case-control study including all patients with SEOC who had been treated at 5 European tertiary gynecologic oncology centers between 1996 and 2011 and patients with either EC or OC matched for age, International Federation of Gynecology and Obstetrics (FIGO) stage, histology, year of diagnosis, and Eastern Cooperative Oncology Group performance score.

Results

The study cohort comprised 77, 132, and 126 patients with SEOC, EC, and OC, respectively. The patient characteristics confirmed an equal distribution of matching factors, and the median follow-up did not differ (P = 0.44). 48.1% of the patients with SEOC showed early FIGO stage I for both EC and OC. The 5-year PFS rates differed between SEOC and EC (76.3% vs 86.3%; P = 0.047) but not the 5-year overall survival rates (71.6% vs 79.8%; P = 0.12) and did not differ between SEOC and OC (76.3% vs 63.8%; P = 0.19 and 71.6% vs 69.3%; P = 0.61, respectively). After the adjustment for the FIGO stage of the 2 components of SEOC, neither PFS nor overall survival rates were different.

Conclusions

Prognosis of patients with SEOC tended to be the same in comparison with matched controls with either one EC or OC. Therefore, it could be considered that patients with SEOC may be eligible for clinical trials of the advanced tumor component if no additional therapy is indicated for the other component.

Copyright © 2013 by IGCS and ESGO

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/IJGConline

For additional oncology content, visit LWW Oncology Journals on Facebook.